Overview

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Status:
Terminated

Trial end date:
2019-12-04

Target enrollment:

Participant gender:

Summary

The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.

Phase:

Phase 1

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Treatments:

Cemiplimab